Date: 2015-04-20
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia, PA
Company: Genticel (France)
Product: ProCervix®
Action
mechanism: vaccine. ProCervix® is an investigational vaccine designed to cure women who are already infected by the HPV16 or HPV18 virus types. It uses the Adenylate Cyclase (CyaA), a protein vector delivering the E7 antigens from HPV 16 and HPV18. The CyaA vector directly targets professional antigen presenting cells. Through its unique delivery mode, CyaA allows the antigen to induce strong CD4+ and CD8+ T cell responses.
Disease: treatment of adult women already infected with human papillomavirus (HPV) genotype 16 or 18
Therapeutic area: Cancer - Oncology - Infectious diseases
Country:
Trial details:
Latest
news: * On April 20th, 2015, Genticel, a French biotechnology company and developer of innovative immunotherapies targeting cancers caused by the human papillomavirus (HPV), announced that the Company presents promising results from a new pharmacology in-vivo study on the potential bivalence of Genticel’s phase 2 immunotherapeutic vaccine candidate, ProCervix®, in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia, PA. The poster is titled “Bivalent adenylate cyclase (CyaA)-based therapeutic vaccines: eradication of tumor cells expressing different antigens over time.” “The results of this study indicate that ProCervix has the potential to eradicate on-going HPV 16 infections, while also providing protection against possible future HPV 18 infections, and vice-versa. These data also suggest that it should be possible to protect and treat patients with multiple different antigens for a given cancer,” said Marie-Christine Bissery, Chief Scientific Officer of Genticel.
